Safety and efficacy of calcium folinate in psoriasis: An observational study

International Journal of Immunopathology and Pharmacology

Volumn 23, Issue 2, 2010, Pages 649-653

  Carlesimo, M ^a   Mari, Elena ^a   Arcese, A ^a   De Angelis, F ^a   Palese, E ^a   Abruzzese, C ^a   De Marco, G ^a   Cattaruzza, M S ^a   Camplone, G ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Calcium folinate; Psoriasis

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; FOLINATE CALCIUM; INFLIXIMAB;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BODY SURFACE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; HUMAN; HYPERTENSION; LOBAR PULMONITIS; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WARTHIN TUMOR;

EID: 77955364599     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201002300229     Document Type: Article

References (15)

1. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatolog Treat 2008; 19:5-21.
2. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004; 113:1664-75.
3. Robinson D Jr, Hackett M, Wong J, Kimball AB, Cohen R, Bala M. Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: An exploration using US healthcare claims data, 2001-2002. Curr Med Res Opin 2006; 22:989-1000.
4. Mrowietz U, Elder JT, Baker J. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res 2007; 298:309-19.
5. Malbris L, Ritchlin CT, Stahle M. Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep 2006; 8:355-63.
6. Tu CL, Oda Y, Komuves L, Bikle DD. The role of the calcium-sensing receptor in epidermal differentiation. Cell Calcium 35 2004; 265-73.
7. Hennings H, Holbrook KA, Yuspa SH. Factors influencing calcium-induced terminal differentiation of mouse epidermal cells. J Cell Physiol 1983; 116:265-81.
8. Braga VM, Hodival KJ, Watt FM. Calcium-indduced changes in distribution and solubility of Cadherins, integrins and their associated cytoplasmic proteins in human keratinocytes. Cell Adhes Commun 1995; 3:201-15.
9. Hennings H, Holbrook KA. Calcium regulation of cell-cell contact and differentiation of epidermal cells in culture. An ultrastructural study. Exp Cell Res 1983; 143:127-42.
10. Denning MF, Dlugosz AA, Williams EK, Szallasi S, Blumberg PM, Yuspa SH. Specific protein kinase C isozymes mediate the induction of keratinocyte differentiation markers by calcium. Cell Growth Differ 1995; 6:149-57.
11. Yang LC, Ng D, Bikle DD. Role of protein kinase Ca in calcium induced keratinocyte differentiation: defective regulation in squamous cell carcinoma. J Cell Physiol 2003; 195:249-59.
12. Fry L, Macdonald A, Almeyda J, Griffin CJ, Hoff brand AV. The mechanism of folate deficiency in psoriasis. Br J Derm 1971; 84:539-44.
13. Vanizor Kural B, Orem A, Cimsit G, Uydu HA, Yandi YE, Alver A. Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients. Clin Chim Acta 2003; 332:23-30.
14. Hermann W, Quast S, Ullrich M, Schuttze H, Bodis M, Geisel J. Hyperhomocysteinemia in high-aged subjects: relation of B-vitamins, folic acid, renal function and methylenetetrahydrofolate reductase mutation. Atherosclerosis 1999; 144:91-101.
15. Hermann W. The importance of hyperomocysteinemia as a risk factor for diseases: an overview. Clin Chem Lab Med 2001; 39:666-74.